Back to Search
Start Over
Efficacy and feasibility of re-irradiation using carbon ions for pancreatic cancer that recurs after carbon-ion radiotherapy
- Source :
- Clinical and Translational Radiation Oncology, Vol 26, Iss, Pp 24-29 (2021), Clinical and Translational Radiation Oncology
- Publication Year :
- 2021
- Publisher :
- Elsevier, 2021.
-
Abstract
- Highlights • Carbon-ion re-irradiation for pancreatic cancer; feasibility and efficacy. • Adjuvant chemotherapy improve local control of re-irradiation using carbon ions. • Carbon-ion radiotherapy for recurrent pancreatic cancer; reasonable option.<br />Background and purpose Patients who receive carbon-ion radiotherapy (C-ion RT) for primary pancreatic cancer may experience locoregional recurrence; however, the treatment options for such patients are limited. We aimed to investigate the feasibility and efficacy of carbon-ion re-irradiation for patients with pancreatic cancer who experienced recurrence after initial C-ion RT. Materials and methods Twenty-one patients with recurrent pancreatic cancer who underwent repeat C-ion RT between December 2010 and November 2016 at our institute were retrospectively evaluated. The sites of post-initial C-ion RT failure were in-field central in 16 patients (76.2%) and marginal in 5 (23.8%). The median doses of initial and repeat C-ion RT were both 52.8 Gy (relative biological effectiveness [RBE]). Thirteen patients (61.9%) received concurrent chemotherapy with re-irradiation, while 11 (52.4%) received adjuvant chemotherapy. Results The median follow-up period after re-irradiation was 11 months. The 1-year local control, progression-free survival, and overall survival rates were 53.5%, 24.5%, and 48.7%, respectively. Toxicity data was obtained from the patients’ charts. Only 1 patient (4.8%) developed grade 3 acute toxicities and none developed grade ≥3 late toxicities. Univariate analysis indicated that patients who received adjuvant chemotherapy had significantly improved local control rates compared with those who did not; the 1-year local control rates were 80.0% and 0.0%, respectively (P = 0.0469). Conclusion Repeating C-ion RT may be a reasonable option with tolerable toxicity for patients with recurrent pancreatic cancers. Adjuvant chemotherapy appears to improve the local control rate. This is the first study to examine re-irradiation using C-ion for recurrent pancreatic cancer after initial C-ion RT.
- Subjects :
- Re-Irradiation
Survival
medicine.medical_treatment
R895-920
D2cc, dose covering 2 cc
GS, gemcitabine plus S1
Gastroenterology
030218 nuclear medicine & medical imaging
Medical physics. Medical radiology. Nuclear medicine
0302 clinical medicine
Original Research Article
CTV, clinical target volume
IMRT, intensity-modulated radiotherapy
RC254-282
Univariate analysis
medicine.diagnostic_test
C-ion RT, carbon-ion radiotherapy
GTV, gross tumour volume
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
PFS, progression-free survival
CT, computed tomography
Oncology
LAPC, locally advanced pancreatic cancer
030220 oncology & carcinogenesis
S-1, tegafur, gimeracil, and oteracil
Toxicity
RBE, relative biological effectiveness
LET, linear energy transfer
PTV, planning target volume
medicine.medical_specialty
EBRT, external beam radiation therapy
SBRT, stereotactic body radiation therapy
OS, overall survival
03 medical and health sciences
Internal medicine
Pancreatic cancer
medicine
Radiology, Nuclear Medicine and imaging
Carbon-ion radiotherapy
Progression-free survival
18F-FDG-PET, 18F-fluorodeoxyglucose positron emission tomography
business.industry
Magnetic resonance imaging
medicine.disease
Radiation therapy
Carbon Ion Radiotherapy
Re-irradiation
LC, local control
business
MRI, magnetic resonance imaging
Subjects
Details
- Language :
- English
- ISSN :
- 24056308
- Volume :
- 26
- Database :
- OpenAIRE
- Journal :
- Clinical and Translational Radiation Oncology
- Accession number :
- edsair.doi.dedup.....2779fb833f41cec5d17800d5dfc07407